Drug Profile
Research programme: monoclonal antibodies - NantiBody
Latest Information Update: 09 Dec 2019
Price :
$50
*
At a glance
- Originator Sorrento Therapeutics
- Developer NantWorks; Sorrento Therapeutics
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Cancer
Most Recent Events
- 04 Jun 2019 NantCell is now called ImmunityBio
- 28 Jan 2019 No recent reports of development identified for research development in Autoimmune-disorders in USA
- 28 Jan 2019 No recent reports of development identified for research development in Cancer in USA